Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;40(3):1019-1030.
doi: 10.1007/s12325-022-02402-z. Epub 2023 Jan 9.

Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Rui Fang  1 , Suiqiong Wang  1 , Yongqian Liu  1 , Jun Xu  2
Affiliations

Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Rui Fang et al. Adv Ther. 2023 Mar.

Abstract

Introduction: First-line treatment with toripalimab plus paclitaxel and cisplatin (TTP) is very effective for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) in China, although its effects on economic burden are unknown. The present study aimed to evaluate the cost-effectiveness of TTP from the perspective of the Chinese healthcare system.

Methods: A Markov model was established to evaluate the cost-effectiveness of first-line treatment with TTP for patients with advanced or metastatic ESCC. Survival data were derived from the JUPITER-06 trial. The costs and utilities were gathered from the literature and a local database. The primary outcomes were total costs, quality-adjusted life year (QALY), and incremental cost-effectiveness ratios (ICERs) at a willingness-to-pay (WTP). One-way and probability sensitivity analyses were used to evaluate the robustness of the model.

Results: The total cost of TTP was $123,646.43 and gained 1.10 QALYs, while the paclitaxel and cisplatin (TP) chemotherapy group yielded 0.84 QALY at cost of $16,259.65. First-line TTP treatment yielded an incremental cost of $7,386.78 with an additional 0.26 QALY, providing an ICER of $28,348.42/QALY, which was lower than the WTP threshold ($36,257.91) in China.

Conclusions: TTP was likely more cost-effective than TP chemotherapy from the perspective of the Chinese healthcare system. This study may provide evidence required to establish decision-making criteria to support guidance for cost-effective selection of an immunotherapeutic regimen.

Keywords: Cisplatin; Cost-effectiveness analysis; Esophageal squamous cell carcinoma; Paclitaxel; Toripalimab.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660.10.3322/caac.21660 . - DOI - PubMed
    1. Abnet CC, Arnold M, Wei WQ. Epidemiology of Esophageal Squamous cell carcinoma. Gastroenterology. 2018;154:360–73. https://doi.org/10.1053/j.gastro.2017.08.023.10.1053/j.gastro.2017.08.023 . - DOI - PubMed
    1. Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037–48. https://doi.org/10.1002/cac2.12197.10.1002/cac2.12197 . - DOI - PubMed - PMC
    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134:783–91. https://doi.org/10.1097/CM9.0000000000001474.10.1097/CM9.0000000000001474 . - DOI - PubMed
    1. Kitagawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2. Esophagus. 2019;16:25–43. https://doi.org/10.1007/s10388-018-0642-8.10.1007/s10388-018-0642-8 . - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources